Orgenesis's revenue per share for the
three
months ended in Dec. 2021 was $0.28.
Orgenesis's revenue per share for the trailing twelve months (TTM) ended in Dec. 2021 was $1.46.
Warning Sign:
Orgenesis Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue Per Share Growth Rate of Orgenesis was 307.50% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was 1.60% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was -4.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Orgenesis's Revenue per Share or its related term are showing as below:
ORGS'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -31.2 Med: -14.1 Max: 30.5
Current: 1.6
During the past 13 years, Orgenesis's highest 3-Year average Revenue Per Share Growth Rate was 30.50% per year. The lowest was -31.20% per year. And the median was -14.10% per year.
ORGS's 3-Year Revenue Growth Rate is ranked worse than 53.87% of 815
companies
in the Biotechnology industry
Industry Median: 4.40
vs ORGS: 1.60
Orgenesis Revenue per Share Historical Data
The historical data trend for Orgenesis's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Orgenesis Annual Data
Trend
Nov12
Nov13
Nov14
Nov15
Nov16
Nov17
Nov18
Dec19
Dec20
Dec21
Revenue per Share
1.04
1.40
0.25
0.36
1.46
Orgenesis Quarterly Data
Feb17
May17
Aug17
Nov17
Feb18
May18
Aug18
Nov18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Revenue per Share
0.10
0.39
0.43
0.36
0.28
Orgenesis Revenue per Share Calculation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Orgenesis's Revenue Per Share for the fiscal year that ended in Dec. 2021 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.46
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orgenesis (NAS:ORGS) Revenue per Share Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Orgenesis Revenue per Share Related Terms
Thank you for viewing the detailed overview of Orgenesis's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Orgenesis Inc is a part of the healthcare sector. It is a fully-integrated biopharmaceutical company focused on developing trans-differentiation technologies for diabetes and vertically integrating manufacturing that can optimize its abilities to scale-up its technologies for clinical trials and eventual commercialization. The group operates in two segments namely CDMO and POC. The company is also engaged in applying its disciplined execution to emerging technologies of other cell therapy markets in such areas as cell-based cancer immunotherapies and neurodegenerative diseases.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.03(1.45%) Volume: 44,682 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:ORGS has been successfully added to your 
